Your browser doesn't support javascript.
loading
The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival.
Danilov, Alexey V; Flinn, Ian W; Davids, Matthew S; Gregory, Beth; Bentur, Ohad; Sidransky, David; Brown, Jennifer R.
Affiliation
  • Danilov AV; City of Hope National Medical Center, Duarte, CA.
  • Flinn IW; Tennessee Oncology, Nashville, TN.
  • Davids MS; CLL Center, Dana-Farber Cancer Institute, Boston, MA.
  • Gregory B; Secura Bio, Inc., Las Vegas, NV.
  • Bentur O; Secura Bio, Inc., Las Vegas, NV.
  • Sidransky D; Johns Hopkins University, Baltimore, MD.
  • Brown JR; CLL Center, Dana-Farber Cancer Institute, Boston, MA. jennifer_brown@dfci.harvard.edu.
Haematologica ; 2024 May 30.
Article in En | MEDLINE | ID: mdl-38813715
ABSTRACT
Not available.
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Haematologica Year: 2024 Document type: Article Affiliation country: Canada
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Haematologica Year: 2024 Document type: Article Affiliation country: Canada